Immunitas TX is a startup based in the United States, most recent round Series B.
Immunitas TX is a company headquartered in the United States. Its most recent tracked round is Series B.
Immunitas TX develops novel immunotherapies targeting CD161 for the treatment of cancer and autoimmune diseases, with programs in clinical and preclinical stages.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.